MR imaging of distal ileal and colorectal chronic inflammatory bowel disease--diagnostic accuracy of 1.5 T and 3 T MRI compared to colonoscopy.

PURPOSE: The aim of this study was to investigate the diagnostic accuracy of MR enterography (MRE) for detection of distal ileal and colorectal inflammatory bowel disease (IBD) and to evaluate whether 3 T MRI can provide a higher diagnostic performance compared to 1.5 T. METHODS: A retrospective review of patients with known or suspected IBD who underwent MRE and colonoscopy within 3 months was performed. For analysis, the bowel was divided into six segments. Compared with colonoscopy, the accuracy values for MRI diagnosis of overall and each magnetic field strength were calculated, and the differences between 1.5 T and 3.0 T were compared. The image quality was scored separately for both field strengths and compared. RESULTS: Eighty-eight patients were included in the study. On a patient basis, MRE had an overall sensitivity of 92.1 % and specificity of 72.0 %. On a segment basis, the sensitivity and specificity were 79.1 % and 93.6 %, respectively. Concerning severely inflamed segments, per-segment sensitivity increased from 79.1 to 94.7 %. The comparison of accuracy values between the two field strengths showed no statistically significant difference. B1 homogeneity and overall artifacts were not significantly different between 3.0 T and 1.5 T imaging. Compared to colonoscopy, MRI found four more fistulas confirmed at subsequent surgery. CONCLUSIONS: MRI has a high diagnostic accuracy for detection of distal ileal and colorectal IBD. 3 T MRI can be considered equivalent but not superior compared to 1.5 T imaging in this context. In addition, our findings suggest MRE to be a valuable tool in detecting surgically relevant pathologies (fistulas) with higher accuracy than colonoscopy.

Clinical practice in radioembolization of hepatic malignancies: a survey among interventional centers in Europe.

OBJECTIVES: A survey was conducted to give an overview about the practice of radioembolization in malignant liver tumors by European centers. METHODS: A questionnaire of 23 questions about the interventional center, preinterventional patient evaluation, the radioembolization procedure and aftercare were sent to 45 European centers. RESULTS: The response rate was 62.2% (28/45). The centers performed 1000 (median = 26) radioembolizations in 2009 and 1292 (median = 40) in 2010. Most centers perform preinterventional evaluation and radioembolization on an inpatient basis. An arterioportal shunt not amendable to preinterventional embolization is considered a contraindication. During preinterventional angiography, the gastroduodenal artery is embolized by 71%, the right gastric artery by 59%, and the cystic artery by 41%. In case of bilobar disease, yttrium-90 microspheres are infused into the common hepatic artery (14%) or separately into left and right hepatic artery (86%). 33% prefer a time interval between right and left liver lobe radioembolization to prevent radiation induced liver disease. 43% of the respondents do not prescribe prophylactic medication after radioembolization. In case of iatrogenic manipulation to the biliary duct system most centers perform radioembolization with prophylactic antibiotics. CONCLUSIONS: Despite standardization of the procedure, there are some differences in how radioembolization of liver tumors is performed in Europe.

Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma.

PURPOSE: This study was designed to investigate the clinical outcome of patients with irresectable, intrahepatic cholangiocarcinoma (IHC) treated with computed tomography (CT)-guided HDR-brachytherapy (CT-HDRBT) for local tumor ablation. METHOD: Fifteen consecutive patients with histologically proven cholangiocarcinoma were selected for this retrospective study. Patients were treated by high-dose-rate internal brachytherapy (HDRBT) using an Iridium-192 source in afterloading technique through CT-guided percutaneous placed catheters. A total of 27 brachytherapy treatments were performed in these patients between 2006 and 2009. Median tumor enclosing target dose was 20 Gy, and mean target volume of the radiated tumors was 131 (±90) ml (range, 10-257 ml). Follow-up consisted of clinical visits and magnetic resonance imaging of the liver every third month. Statistical evaluation included survival analysis using the Kaplan-Meier method. RESULTS: After a median follow-up of 18 (range, 1-27) months after local ablation, 6 of the 15 patients are still alive; 4 of them did not get further chemotherapy and are regarded as disease-free. The reached median local tumor control was 10 months; median local tumor control, including repetitive local ablation, was 11 months. Median survival after local ablation was 14 months and after primary diagnosis 21 months. CONCLUSION: In view of current clinical data on the clinical outcome of cholangiocarcinoma, locally ablative treatment with CT-HDRBT represents a promising and safe technique for patients who are not eligible for tumor resection.